SIGA Technologies Inc. (SIGA) exhibits 68.6% gross margins and 42.7% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 4.8x enterprise multiple and 4.8% implied options volatility.
Sustained 68.6% gross profitability converts into 25.1% operating margin and 42.7% ROIC, outpacing sector cost of capital.
ROIC: 42.7% // GM: 68.6%YoY revenue trajectory of -31.8% paired with 19.03% free cash flow yield supports self-funded R&D and capital return.
REV YOY: -31.8% // FCF YLD: 19.03%Altman Z-Score of 8.22 and Piotroski F-Score of 6/9 indicate low near-term refinancing stress.
ALTMAN Z: 8.22 // F-SCORE: 6/9Trading at 9.8x trailing P/E (9.1x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 9.8x // EV/EBITDA: 4.8xOptions market prices a ±5.2% implied move with a 0.85 put/call ratio around $3.04 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend 24.6% net margins.
NET MARGIN: 24.6% // D/E: 0.45x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for SIGA & activate live FRED threshold breach alerts.